Astellas and Boehringer Ingelheim Reach Settlement Agreement with Ranbaxy on Flomax Patent Case
TOKYO and RIDGEFIELD, Conn., November 08, 2007 /PRNewswire/ -- Astellas Pharma Inc. and Boehringer Ingelheim Pharmaceuticals, Inc. (a subsidiary of Boehringer Ingelheim Corporation) announced today that the two companies have reached a settlement agreement with Ranbaxy to enter into a stipulation of dismissal of the pending U.S. litigation with regard to U.S. Patent No. 4,703,063 for Flomax(R) (tamsulosin hydrochloride) capsules, a treatment for the signs and symptoms of benign prostatic hyperplasia (BPH).
As a result of this settlement, the case will be dismissed without prejudice. The settlement of the litigation provides Ranbaxy with the opportunity to launch a generic tamsulosin hydrochloride product on March 2, 2010, prior to the expiration of pediatric exclusivity if such is granted by the FDA. Further terms of the settlement will not be disclosed.
For more information, please contact: Kate O'Connor, Communications & Public Relations Boehringer Ingelheim Pharmaceuticals, Inc. Tel: 203-791-6250 Mobile: 917-446-7400 Astellas Pharma Inc. Corporate Communications Tel: +81-3-3244-3201 Fax: +81-3-5201-7473 http://www.astellas.com
CONTACT: Kate O'Connor, Communications & Public Relations of BoehringerIngelheim Pharmaceuticals, Inc., Tel, +1-203-791-6250, Mobile,+1-917-446-7400; or Corporate Communications of Astellas Pharma Inc., Tel,+81-3-3244-3201, Fax, +81-3-5201-7473
Web site: http://www.astellas.com/
Terms and conditions of use apply
Copyright © 2007 PR Newswire Association LLC. All rights reserved.
A United Business Media Company
Posted: November 2007